Imagyn licenses MicroSpan line to Ethicon:
This article was originally published in Clinica
Imagyn Medical Technologies is to license its MicroSpan microhysteroscopy product line to Ethicon. Under the terms of the agreement, which includes cash payments of $4 million with certain milestones, Imagyn, of Newport Beach, California, will initially supply the products to Ethicon for up to two years on an exclusive basis. Ethicon will have a worldwide, exclusive licence to manufacture and market the products for ten years. After this time, Somerville, New Jersey-based Ethicon will own the products. Imagyn recently announced the divestiture of its impotence product lines to Timm Research for $25.8 million. The company is looking at options - including sale or alliances - for its remaining non-strategic assets.
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.